Chemistry:SH-BC-893
From HandWiki
SH-BC-893 is a synthetic sphingolipid derivative which has been researched for the treatment of cancer, and also shows broad-spectrum antiviral properties as well as potential application in the treatment of obesity. It acts by decreasing cell surface expression of several different nutrient transporter proteins, which can then starve cancer cells of nutrients as well as blocking viral entry into cells via endosomal pathways.[1][2][3][4][5][6]
See also
References
- ↑ "Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways". The Journal of Clinical Investigation 126 (11): 4088–4102. November 2016. doi:10.1172/JCI87148. PMID 27669461.
- ↑ "Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6". Journal of Cell Science 131 (12). June 2018. doi:10.1242/jcs.213314. PMID 29848659.
- ↑ "Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs". Molecular & Cellular Proteomics 18 (3): 408–422. March 2019. doi:10.1074/mcp.RA118.001053. PMID 30482847.
- ↑ "Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity". EMBO Molecular Medicine 13 (8). August 2021. doi:10.15252/emmm.202013086. PMID 34231322.
- ↑ "Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics". Nucleic Acids Research 51 (4): 1583–1599. February 2023. doi:10.1093/nar/gkad023. PMID 36727438.
- ↑ "Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo". Scientific Reports. May 2026. doi:10.1038/s41598-026-51335-y. PMID 42115643.
 |  |
